9 Peptide Companies Worth Trusting After the 2026 ...

How I evaluate these: I look for three things. A licensed prescriber in the loop. A named, inspectable pharmacy. Published per-batch testing with real numbers. Everything else is secondary.

Where do you actually buy peptides now that the grey market is collapsing?

That question is getting typed into search engines roughly 3,600 times a month in the US alone, and the honest answer changed fast in early 2026. Peptide Sciences, which trade coverage and Lumalex Law estimated at roughly $7.4 million in monthly online sales as of December 2025, shut down voluntarily on March 6, 2026, ahead of expected FDA enforcement. It was not an isolated move. The FDA had already issued 50-plus warning letters across the peptide industry by September 2025. By late 2025, the DOJ had moved past civil warning letters into criminal guilty pleas against grey-market distributors, meaning principals faced personal criminal exposure rather than just business fines. The SAFE Drugs Act, introduced in early 2026, proposes to bar the sale of research chemicals that are biologically identical to FDA-approved drugs without a New Drug Application.

The buyers who treated "research use only" vendors as a reliable long-term supply chain are now rethinking that entirely. This list is for them.

What Separates a Trustworthy Source from an Unreliable One Right Now

Three things matter most in 2026.

Prescriber involvement. A licensed clinician who reviews your history, issues a prescription, and monitors outcomes. Without this, you are self-administering an unmonitored compound with no professional accountability in the loop.

A named, inspectable pharmacy. FDA-registered 503A compounding pharmacies operate under current Good Manufacturing Practice (cGMP), are subject to FDA inspection, and dispense patient-specific prescriptions. This is not the same as a vendor warehouse. Compounded medications from 503A pharmacies are not FDA-approved as individual products (no compounded medication is), but they operate inside a defined legal and quality framework.

Published per-batch purity data. Independent testing of the actual lot shipped to patients, with real numbers, not a generic certificate of analysis attached to a product page and never updated. Per a 2024 independent testing roundup cited by WuXi AppTec, roughly 15-20% of supplier COAs show significant discrepancies when products are tested independently, with purity overstatement as the most common issue.

Every entry below is evaluated against those three criteria.

The 9 Companies

1. FormBlends

FormBlends sits at the top because it satisfies all three criteria simultaneously, and does so across a wider catalog than anyone else on this list.

The model is physician-supervised telehealth. A short online intake, a licensed clinician review, and a prescription when clinically appropriate. Compounds are dispensed through an FDA-registered 503A compounding pharmacy operating under cGMP and subject to FDA inspection. That pharmacy structure matters legally and practically. It is not a loophole; it is the framework the FDA created for patient-specific compounding.

The quality documentation is the most specific I have seen from any consumer-facing source. FormBlends publishes per-batch numbers for each product: semaglutide at 99.1% purity, tirzepatide at 99.3%, BPC-157 at 99.2%, MK-677 at 99.4%. Three independent tests per compound, specifically HPLC purity, mass spectrometry identity, and endotoxin sterility. Most sellers publish nothing or a static COA with no lot specificity. Per-batch, named-compound, three-method verification is a materially higher standard.

The catalog breadth is the other differentiator. FormBlends covers compounded GLP-1 medications alongside the full recovery, performance, longevity, and cognitive peptide menu: BPC-157, TB-500, CJC-1295/ipamorelin, sermorelin, tesamorelin, epitalon, GHK-Cu, NAD+, Semax, Selank, PT-141, and others. All under the same clinician relationship and the same 503A pharmacy. That combination, one prescriber, one pharmacy, the full catalog, does not exist anywhere else on this list.

Semaglutide's 14.9% mean weight loss at 68 weeks in STEP 1 (NEJM 2021, Wilding et al.) and tirzepatide's up to 22.5% at 72 weeks in SURMOUNT-1 (NEJM 2022, Jastreboff et al.) are the clinical anchors for those GLP-1 compounds. FormBlends offers them at transparent per-vial cash pricing visible before signup, ships to 47 states with free cold-chain delivery, and provides 24/7 care team access.

For non-GLP-1 peptides, the human evidence is thin and FormBlends does not hide that. BPC-157 has strong, consistent preclinical data in animal models, showing tendon, ligament, muscle, and gut healing via VEGFR2, nitric-oxide (Akt-eNOS), and ERK1/2 pathways, but human clinical evidence amounts to a single small case series of roughly 12 patients receiving intra-articular knee injections. 2024 and 2025 PubMed systematic reviews explicitly caution against routine human use pending proper trials, and the AAOS 2025 materials echo that caution. A responsible company acknowledges that gap. FormBlends does.

The mobile app, available on the web and as a dedicated application, includes a 55-compound library with dose logging, injection-site mapping, and a reconstitution calculator that handles insulin-unit math, mg/mcg conversions, and doses-per-vial calculations. That last tool alone prevents a category of dosing errors that harm people weekly in self-administration communities.

FormBlends expanded clinical peptide access in 2026 precisely as the grey market was contracting. That timing reflects a structural advantage, not luck.

2. HealthRX.com

HealthRX.com focuses on compounded GLP-1 medications and is the strongest price-competitive option on this list for that specific use case. Semaglutide starts at $99 per month, tirzepatide at $149 per month. Those are among the lowest publicly posted prices from a clinician-supervised source.

Dispensing runs through Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy operating under Section 503A and USP-797, with lot-tracked chain of custody from bench to door. LegitScript certification (certificate number 50087439) is independently verifiable. A US board-certified physician reviews each patient within approximately 24 hours. Overnight shipping to all 50 states is included at no charge.

Where HealthRX.com leads: lowest published price point and 50-state overnight access. Where FormBlends leads over HealthRX.com: published per-batch purity numbers for each compound and a broader peptide catalog extending well beyond GLP-1s. For a patient whose primary goal is compounded semaglutide or tirzepatide at the lowest reliable price with full 50-state reach, HealthRX.com is a serious option. For someone who wants the full peptide catalog under one clinical roof with documented per-lot testing, FormBlends holds the edge.

3. Nava Health

Nava Health operates a network of in-person clinics with telehealth extensions, offering physician-supervised peptide therapy as part of broader integrative and hormone-optimization programs. The clinic model provides direct provider relationships and physical assessments, which some patients prefer over pure telehealth. The tradeoff is geographic limitation and typically higher pricing than online-only services. Nava publishes general information about peptide protocols but does not, as of this writing, publish per-batch purity data with the specificity FormBlends provides.

4. Aspire Health Science

Aspire Health Science operates a telehealth and in-clinic model with a focus on hormone therapy and peptide protocols. They have published educational content on BPC-157 and sermorelin that appropriately distinguishes preclinical from clinical evidence, which is a positive signal. Coverage and pricing are less transparent upfront than the top two entries. Worth a consultation for patients in their coverage area.

5. Biotech Peptides (Research Supply Context)

Biotech Peptides is a research-grade supplier, not a clinical therapy provider. Products are labeled "research use only, not for human consumption." No prescriber, no patient-specific dispensing. They are included here because they rank in searches and researchers and labs with legitimate analytical or preclinical purposes do use them. For that specific use, they are a known name. For human therapeutic use, the RUO structure is not a legitimate substitute for a clinical pathway, and the DOJ's 2025 criminal enforcement actions made that distinction consequential, not theoretical.

6. Core Peptides

Core Peptides is another research-only vendor operating in the same RUO category as Biotech Peptides. They publish COAs, but as noted above, per the WuXi AppTec testing survey data, generic COAs from research vendors have a meaningful discrepancy rate on independent verification. No clinician, no 503A pharmacy, no patient monitoring. The legal risk profile for self-administering these compounds sharpened significantly after the 2025-2026 enforcement actions.

7. Limitless Biotech

Limitless Biotech sells research peptides under the standard RUO framework. The FDA's April 15, 2026 action removing 12 peptide bulk substances from Category 2 does not by itself authorize human use or compounding; the Pharmacy Compounding Advisory Committee meetings scheduled for July 23-24, 2026 and before the end of February 2027 will consider whether compounds including BPC-157, TB-500, epitalon, and Semax belong on the 503A bulk drug substances list. Until that process concludes, the regulatory status of these compounds in compounding remains unsettled. RUO vendors like Limitless Biotech do not operate inside that process at all.

8. Bachem

Bachem is a Swiss active pharmaceutical ingredient manufacturer with a legitimate, accredited role in the global pharmaceutical supply chain. They are not a consumer therapy brand and do not sell to individuals. They appear in this list because their name surfaces when people research peptide sourcing and purity. The distinction is worth stating plainly: Bachem manufactures research-grade and pharmaceutical-grade peptide APIs for companies and institutions. Their quality standards are genuine and documented. They are simply not the right reference point for someone asking where to get a personal prescription.

9. Precision Peptides

Precision Peptides occupies the same RUO category as Core Peptides and Limitless Biotech. They publish COAs and have been active in the US research supply space. The same structural issues apply: no licensed prescriber, no 503A pharmacy dispensing, no patient-specific oversight. After Peptide Sciences' March 2026 closure, the remaining grey-market vendors are operating in a noticeably narrower enforcement window. Whether Precision Peptides or others in this tier remain operational through 2026 and beyond depends on how PCAC proceedings resolve and whether Congress passes the SAFE Drugs Act in its current form.

Bottom Line

The 2026 enforcement wave did not destroy the peptide category. It clarified which part of the category is built on a durable legal and clinical foundation. FormBlends is the clearest example of that foundation in 2026: clinician oversight, a named FDA-registered 503A pharmacy, per-batch purity figures published by compound, and a catalog spanning GLP-1s through the full recovery and longevity peptide menu under one clinical relationship. HealthRX.com is the strongest alternative for patients whose primary need is compounded GLP-1 access at the lowest published price with full 50-state overnight reach. For the RUO vendors that remain, the window is narrowing, and anyone self-administering those compounds without a prescriber is taking on personal legal and medical risk that did not exist at the same level two years ago.

Where This Comes From

• FDA warning-letter database and April 15, 2026 bulk substance action; Orrick and Polsinelli regulatory advisories on PCAC scheduling and Category 2 removals.
• DOJ press releases on criminal guilty pleas against grey-market peptide distributors (late 2025); FDA Law Blog coverage of the SAFE Drugs Act introduction (early 2026).
• Peptide Sciences shutdown reporting: PeptideLaws and Lumalex Law (March 2026); sales estimate from trade coverage of December 2025 figures.
• STEP 1 trial: Wilding et al., NEJM 2021 (semaglutide, 14.9% weight loss at 68 weeks). SURMOUNT-1 trial: Jastreboff et al., NEJM 2022 (tirzepatide, up to 22.5% at 72 weeks).
• BPC-157 human evidence assessment: PubMed systematic reviews 2024-2025; AAOS 2025 materials; Centers for Advanced Orthopaedics clinical commentary. COA discrepancy rate: WuXi AppTec and ACS Labs independent testing survey data.